- Home
- BMR vs MRSN Comparison
BMR vs MRSN Comparison
Compare BMR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- MRSN
- Stock Information
- Founded
- BMR 2009
- MRSN 2001
- Country
- BMR Israel
- MRSN United States
- Employees
- BMR N/A
- MRSN N/A
- Industry
- BMR Computer Software: Prepackaged Software
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BMR Technology
- MRSN Health Care
- Exchange
- BMR Nasdaq
- MRSN Nasdaq
- Market Cap
- BMR 47.4M
- MRSN 47.1M
- IPO Year
- BMR 2023
- MRSN 2017
- Fundamental
- Price
- BMR $2.15
- MRSN $8.00
- Analyst Decision
- BMR
- MRSN Strong Buy
- Analyst Count
- BMR 0
- MRSN 3
- Target Price
- BMR N/A
- MRSN $33.00
- AVG Volume (30 Days)
- BMR 238.9K
- MRSN 60.7K
- Earning Date
- BMR 08-13-2025
- MRSN 11-13-2025
- Dividend Yield
- BMR N/A
- MRSN N/A
- EPS Growth
- BMR N/A
- MRSN N/A
- EPS
- BMR N/A
- MRSN N/A
- Revenue
- BMR $3,131,000.00
- MRSN $34,769,000.00
- Revenue This Year
- BMR $21.21
- MRSN N/A
- Revenue Next Year
- BMR N/A
- MRSN N/A
- P/E Ratio
- BMR N/A
- MRSN N/A
- Revenue Growth
- BMR 5.96
- MRSN 16.14
- 52 Week Low
- BMR $1.86
- MRSN $5.21
- 52 Week High
- BMR $6.59
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- BMR 30.65
- MRSN 41.31
- Support Level
- BMR $2.26
- MRSN $8.00
- Resistance Level
- BMR $2.90
- MRSN $9.87
- Average True Range (ATR)
- BMR 0.16
- MRSN 0.64
- MACD
- BMR -0.06
- MRSN -0.30
- Stochastic Oscillator
- BMR 3.57
- MRSN 6.44
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.